Cleo Diagnostics rises on appointing partner to start US market access program

CLEO Diagnostics

02/04/2024 03:38

** Shares of Australia's Cleo Diagnostics  COV.AX  rise as
much as 11.8% to A$0.190, their biggest intraday gain since Jan.
31
    ** Stock at its highest since March 20
    ** Medical diagnostics co says it has appointed New
York-based healthcare industry consultancy, HcFocus, to commence
its U.S. market access program
    ** The U.S. program will focus on a roadmap to achieve FDA
approval, reimbursement, a clinical trial, as well as industry
and doctor engagement 
    ** Stock down ~3% YTD as of last close

 (Reporting by Neha Soni in Bengaluru)
 ((Neha.Soni@thomsonreuters.com))